Resverlogix Corp.

Resverlogix Corp.

September 17, 2007 13:00 ET

Stella M. Thompson Joins Resverlogix Board of Directors

CALGARY, ALBERTA--(Marketwire - Sept. 17, 2007) - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that Stella Thompson has joined the Board of Directors. On the subject of her appointment Stella Thompson said, "I am very pleased to be joining the Board of Resverlogix because of the exciting prospects and the high caliber talent that exists on Board and the management team."

"We are extremely pleased with the addition of Stella Thompson to Resverlogix's Board as she has over thirty years of experience and expertise in corporate governance, with membership on a number of corporate and not-for-profit boards, as well as executive and management positions at a number of large corporations," stated Donald McCaffrey, President and CEO of Resverlogix. "Stella will assist in facilitating strategic, organizational and operational excellence."

Stella M. Thompson is currently principal consultant and co-founder of Governance West Inc., a Calgary based consulting firm specializing in assisting boards of directors to achieve excellence in the governance of their organizations. Currently, Stella serves on a number of Boards including the Atomic Energy of Canada Ltd., Alberta's Electricity Balancing Pool, the Calgary Airport Authority, Genome Alberta and Talisman Energy Inc. In prior years, she also served on a number of publicly traded companies and science based organizations. Prior to commencing her consulting practice and directorships in 1992, Stella worked for over thirty years in diverse roles in the oil and gas business in Australia and Canada with a number of major oil companies. Stella has a BA and an MA in Economics.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-l. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information